CANVAC 8 DHPPiL

Indications

• Acute respiratory infection
• Conjunctivitis
• Gastroenteritis
• Cystitis
• Meningitis
• Pneumonia

Dosage

Children: There is no specific dosage as adenovirus infections are generally self-limiting. Symptomatic treatment is advised.

Adults: There is no specific dosage as adenovirus infections are typically self-limiting. Supportive care is recommended.

Mechanism of action

Adenoviruses infect host cells through interactions with specific receptors on the cell surface, facilitating virus entry and subsequent release of viral DNA into the host cell nucleus. The viral DNA then utilizes the host cell's machinery to replicate and produce new viral particles, eventually leading to cell lysis and the release of new virions.

Pharmacodynamics

The clinical manifestations of adenovirus infections can range widely depending on the serotype and host factors. The immune response plays a critical role in controlling the infection, with both innate and adaptive immunity contributing to viral clearance. In general, adenovirus infections stimulate a robust immune response, which may cause symptoms such as fever, sore throat, and conjunctivitis.

Pharmacokinetics

Adenoviruses are typically transmitted via respiratory droplets or direct contact with contaminated surfaces. After exposure, the viruses can replicate in the epithelial cells of the respiratory tract, conjunctiva, or gastrointestinal tract. The viral shedding can occur for several days to weeks, depending on the individual's immune response. Adenoviruses do not have a specific treatment, and management focuses on symptomatic relief and supportive care.

Adverse effects

• Fever
• Sore throat
• Cough
• Conjunctivitis
• Diarrhea
• Pneumonia
• Bronchitis
• Sinusitis

Precautions

• In immunocompromised patients, adenovirus can cause severe disease.
• Caution should be exercised in individuals with underlying respiratory conditions.

Pregnancy

Adenovirus infections can occur during pregnancy, but specific risks to the fetus are not well established. Consultation with healthcare providers is advised.

Breast-feeding

Adenovirus can be transmitted through breast milk; however, the clinical significance is not clear. Breastfeeding mothers should consult healthcare professionals if they are infected.

Storage

Adenoviruses are laboratory-based entities and are typically stored in controlled environments within laboratory settings, rather than as commercially available drugs.

Indications

• Measles
• Mumps
• Rubella
• Yellow fever
• Varicella (chickenpox)
• Rotavirus

Dosage

Children: Refer to specific vaccine guidelines for paediatric dosing.

Adults: Refer to specific vaccine guidelines for adult dosing.

Mechanism of action

Attenuated vaccines work by mimicking a natural infection. The weakened pathogen replicates in the body, stimulating the immune system to produce a response against it, which includes the activation of T-cells and the production of antibodies. This prepares the immune system to recognize and fight off the pathogen if exposed in the future.

Pharmacodynamics

The pharmacodynamics of attenuated vaccines involve the interaction of the attenuated pathogen with the host's immune system. Upon administration, the vaccine induces both humoral (antibody-mediated) and cell-mediated immunity. This leads to the development of memory cells that ensure a faster and more effective response upon subsequent exposure to the actual pathogen.

Pharmacokinetics

Attenuated vaccines are generally administered via subcutaneous or intramuscular injection. The pharmacokinetics are characterized by the distribution of the vaccine components within the body, with the attenuated organisms replicating locally and inducing an immune response. The onset of immunity typically occurs within weeks, and the duration of immunity can vary depending on the specific vaccine.

Contra-indications

• Severe immunodeficiency
• Pregnant women (specific live attenuated vaccines)
• Severe allergic reactions to vaccine components

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Low-grade fever
• Malaise
• Rash
• Rare neurological complications (e.g., Guillain-Barré syndrome)

Interactions

• Immunosuppressive agents (may reduce vaccine efficacy)
• Blood products (may interfere with immune response to vaccine)
• Other live vaccines (timing may affect immune response)

Precautions

• History of allergic reactions to previous vaccinations
• Presence of active infections
• Chronic illnesses that may affect immune response

Pregnancy

Live attenuated vaccines are generally contraindicated during pregnancy due to potential risks to the fetus.

Breast-feeding

Most live attenuated vaccines are considered safe during breastfeeding, but caution and consultation with a healthcare provider are advised.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Injectable suspension
• Oral suspension
• Lyophilized powder for reconstitution

Indications

• Pain management
• Inflammation
• Infections
• Chronic diseases
• Allergic reactions

Dosage

Children: Dosage for paediatric canines (puppies) also varies widely depending on the specific medication, age, and weight of the puppy. Veterinary guidance is crucial for determining appropriate doses.

Adults: Dosage for adult canines varies based on the specific medication and condition being treated. It is essential to consult veterinary guidelines or a veterinarian for appropriate dosing.

Mechanism of action

The mechanism of action of canine medications varies widely depending on the specific drug class. For example, non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase enzymes (COX-1 and COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Antibiotics may work by inhibiting bacterial cell wall synthesis or protein synthesis, while corticosteroids reduce inflammation by inhibiting immune response.

Pharmacodynamics

Pharmacodynamics in canines involves understanding how drugs affect the body, including their therapeutic effects and potential side effects. For example, NSAIDs provide analgesic and anti-inflammatory effects, while antibiotics target specific pathogens to eliminate infections. The response to drugs can vary based on factors such as breed, age, and overall health status.

Pharmacokinetics

Pharmacokinetics in canine patients encompasses the absorption, distribution, metabolism, and excretion of drugs. Canine physiology can influence these processes; for example, drugs may be absorbed more quickly in dogs due to differences in gastrointestinal pH and transit time. Metabolism often occurs in the liver, with variations based on breed and age affecting drug clearance. Excretion primarily takes place through the kidneys.

Pregnancy

Safety during pregnancy has not been established. Consult a veterinarian for guidance.

Breast-feeding

Safety during lactation has not been established. Consult a veterinarian for guidance.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Prevention of canine distemper through vaccination
• Supportive treatment for infected dogs

Dosage

Children: No specific dosage available, refer to guidelines for vaccination schedules.

Adults: No specific dosage available, refer to guidelines for vaccination schedules.

Mechanism of action

Canine distemper virus primarily infects and replicates in lymphoid tissue, leading to immune suppression, and subsequently affects epithelial tissues in the respiratory, gastrointestinal, and nervous systems. The virus enters host cells via the signaling lymphocytic activation molecule (SLAM) receptor, which is expressed on immune cells, facilitating its spread throughout the body.

Pharmacodynamics

The immune response to CDV involves both humoral and cellular immunity. Vaccination induces an immune response that generates neutralizing antibodies, which prevent viral entry into host cells. Infected animals may develop severe immunosuppression, making them susceptible to secondary infections. The clinical manifestations depend on the severity of the infection and the host's immune response.

Pharmacokinetics

The pharmacokinetics of canine distemper virus are not typically described in terms of absorption, distribution, metabolism, and excretion like conventional drugs. Instead, the focus is on viral replication and the host immune response. The incubation period for distemper can vary but generally ranges from 1 to 2 weeks. The duration of the immune response post-vaccination can last for several years, depending on the type of vaccine used.

Pregnancy

No specific data available on the effects of distemper treatment in pregnant individuals, consult relevant guidelines.

Breast-feeding

No specific data available on the effects of distemper treatment during breastfeeding, consult relevant guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Clinical term 1
• Common term 1
• Clinical term 2
• Common term 2

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Dose acts by modulating the activity of specific neurotransmitter receptors and ion channels, influencing various physiological pathways. Its precise mechanism may involve interactions with G-protein coupled receptors, leading to downstream signaling effects that impact cellular responses.

Pharmacodynamics

Dose exhibits a range of effects depending on the dosage and target tissues. It is known to alter neurotransmitter release, affect ion conductance, and influence metabolic pathways, thereby contributing to its therapeutic efficacy and potential side effects.

Pharmacokinetics

Dose is generally absorbed following administration, with peak plasma concentrations occurring within a specified timeframe. Its distribution is influenced by tissue binding and permeability across cell membranes. The drug is metabolized primarily in the liver, with metabolites being excreted via renal and biliary routes. The half-life can vary based on individual patient factors, including age, liver function, and other concurrent medications.

Indications

• Gastroenteritis caused by Salmonella enterica serotype Grippotyphosa
• Systemic infections in immunocompromised patients
• Foodborne illness outbreaks

Dosage

Children: Refer to clinical guidelines for appropriate antibiotic therapy based on susceptibility testing.

Adults: Refer to clinical guidelines for appropriate antibiotic therapy based on susceptibility testing.

Mechanism of action

Grippotyphosa invades the intestinal epithelium, evading the host's immune response. It utilizes a type III secretion system to inject virulence factors into host cells, promoting bacterial entry and survival within macrophages, which leads to systemic infection.

Pharmacodynamics

The pathogenicity of Grippotyphosa is characterized by its ability to induce inflammation and disrupt the intestinal barrier. The bacteria can replicate within macrophages, leading to prolonged immune response and potential dissemination into the bloodstream, causing systemic illness. Antibiotic susceptibility may vary, necessitating sensitivity testing.

Pharmacokinetics

As a bacterial pathogen, Grippotyphosa is not a drug with pharmacokinetic properties. However, when treated with antibiotics, the pharmacokinetics of the chosen antibiotic will dictate its effectiveness against the bacteria. Typically, antibiotics are absorbed, distributed, metabolized, and excreted in a way that targets the infection site effectively.

Pregnancy

Consult a healthcare professional before use. Data on safety in pregnancy is limited.

Breast-feeding

Consult a healthcare professional before use. Limited data on excretion in breast milk.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Croup (laryngotracheobronchitis)
• Bronchiolitis
• Pneumonia
• Upper respiratory tract infections

Mechanism of action

Parainfluenza viruses enter host cells and replicate by binding to specific receptors on the cell surface, mainly through the hemagglutinin-neuraminidase (HN) and fusion (F) proteins. Once inside the cell, the viral RNA is released and hijacks the host's cellular machinery to produce viral proteins and replicate the viral genome, leading to the assembly of new virions. This process ultimately results in cell lysis and the release of new viral particles, facilitating the spread of infection.

Pharmacodynamics

The immune response to parainfluenza infection involves both innate and adaptive mechanisms. The initial response includes the release of cytokines and activation of immune cells, such as macrophages and T cells. This immune response aims to control viral replication and clear the virus from the respiratory tract. Symptoms associated with parainfluenza infections, such as cough and difficulty breathing, are often a result of inflammation and airway obstruction due to the immune response.

Pharmacokinetics

As a virus, parainfluenza does not have pharmacokinetics in the traditional sense applied to drugs; however, the viral replication cycle is crucial for understanding its behavior in the human body. Following exposure, the incubation period typically ranges from 2 to 7 days. The virus can be shed from the respiratory tract for several days, with peak shedding occurring at the onset of symptoms. The immune system gradually controls the infection, leading to the resolution of symptoms.

Adverse effects

• Fever
• Rhinorrhea
• Cough
• Sore throat
• Wheezing
• Shortness of breath
• Lethargy
• Croup
• Pneumonia

Precautions

• Monitor respiratory status in patients with underlying respiratory conditions
• Use caution in immunocompromised patients

Pregnancy

There are no known specific risks to pregnant women, but caution is advised.

Breast-feeding

Generally considered safe, but consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.